EDIT vs EPRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EPRX Captures Institutional Edge (2โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) driven by superior Growth & Margin, Momentum & Technical while EDIT counters with relative strength in Options & Structure. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus EPRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against EPRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EDIT | EPRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $336.5M | $525.4M | Larger Scale | EPRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +37.4% | +0.0% | Higher Growth | EDIT |
| Operating Margin (TTM) Profitability | -167.0% | 0.0% | Higher Margin | EPRX |
| Net Profit Margin Profitability | -144.9% | 0.0% | Higher Margin | EPRX |
| Return on Equity (ROE) Capital Efficiency | -147.4% | -56.4% | Higher ROE | EPRX |
| 52-Week Range Position Momentum | 11% ($2โ$4) | 50% ($6โ$9) | Stronger Trend | EPRX |
| Beta / 30D Volatility Risk Regime | 2.32ฮฒ ยท 102% Vol | 1.70ฮฒ ยท 77% Vol | Lower Realized Risk | EPRX |
| Unified Institutional Score Composite Signal | 51.6 / 100 (HOLD) | 34.1 / 100 (SELL) | Higher Composite | EDIT |